scholarly journals Health-Related Quality of Life of Patients with Hidradenitis Suppurativa Measured with the 15D Instrument and Comparison with the General Population and Patients with Psoriasis

2017 ◽  
Vol 4 (3) ◽  
pp. 131-135 ◽  
Author(s):  
Nicolas Kluger ◽  
Harri Sintonen ◽  
Martta Ranta ◽  
Martina Serlachius
Author(s):  
Pavel V. Chernyshov ◽  
Andrew Y. Finlay ◽  
Lucia Tomas-Aragones ◽  
Francoise Poot ◽  
Francesca Sampogna ◽  
...  

Knowledge on hidradenitis suppurativa/acne inversa (HS) is rapidly increasing. HS has a profound impact on patients and their family life. Several factors, such as comorbidities, unemployment and HS severity, make this impact even more severe. The most widely used instrument to measure this impact is the dermatology-specific DLQI. We also identified six HS-specific health-related quality of life (HRQoL) instruments. Of them, HIDRAdisk, HSIA, HiSQOL and HSQoL-24 are better validated but there is still lack of experience of its use. Several treatment methods showed positive effect on patients’ HRQoL. Surgery remains a method with a substantial positive effect on HRQoL. Several studies confirming a positive effect of adalimumab on the HRQoL of patients with HS were published during the last three years. Data on the influence of several other biologics on HRQoL of HS patients are controversial or based on studies with a small number of patients.


Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1500 ◽  
Author(s):  
Rebecca V. Steenaard ◽  
Laura A. Michon ◽  
Harm R. Haak

Insight into the health-related quality of life (HRQoL) impact of adrenocortical carcinoma (ACC) is important. The disease and its treatment options potentially have an impact on HRQoL. For patients with limited survival, HRQoL research is of utmost importance. We will therefore provide an overview of HRQoL studies in patients with ACC. We found six studies that measured HRQoL in 323 patients with ACC (3 cross-sectional, 1 cohort, 2 trials), all indicating a reduced HRQoL compared to the general population. The FIRMACT trial found that HRQoL of patients with ACC was reduced compared to the general population, and that chemotherapy-mitotane further reduced HRQoL even though survival improved. Clinical aspects of the disease, including cortisol and aldosterone production and adrenal insufficiency have shown great impact on HRQoL in benign disease, even after the recovery of hormonal status. However, the impact of malignant adrenal disease and treatment options on HRQoL including adrenalectomy, radiotherapy, mitotane therapy, and chemotherapy have not been sufficiently studied in patients with ACC. Although the number of HRQoL studies in patients with ACC is limited, the existing literature does indicate that ACC has a large impact on patients’ HRQoL, with disease specific aspects. Further HRQoL research in patients with ACC is essential to improve patient-centered care, preferably by using an ACC-specific HRQoL questionnaire.


PeerJ ◽  
2013 ◽  
Vol 1 ◽  
pp. e98 ◽  
Author(s):  
Robert Johansson ◽  
Per Carlbring ◽  
Åsa Heedman ◽  
Björn Paxling ◽  
Gerhard Andersson

2010 ◽  
Vol 120 (1-3) ◽  
pp. 126-132 ◽  
Author(s):  
Mascha C. ten Doesschate ◽  
Maarten W.J. Koeter ◽  
Claudi L.H. Bockting ◽  
Aart H. Schene

Circulation ◽  
2019 ◽  
Vol 139 (Suppl_1) ◽  
Author(s):  
Marialaura Bonaccio ◽  
Augusto Di Castelnuovo ◽  
Simona Costanzo ◽  
Amalia De Curtis ◽  
Mariarosaria Persichillo ◽  
...  

2015 ◽  
Vol 25 (suppl_3) ◽  
Author(s):  
L Scalone ◽  
PA Cortesi ◽  
LG Mantovani ◽  
R Ciampichini ◽  
G Cesana

Sign in / Sign up

Export Citation Format

Share Document